|
|
| Line 1: |
Line 1: |
|
| |
|
| {{PBI|Human herpesvirus 8 (KSHV)}} | | {{PBI|Mycoplasma pneumoniae}} |
| :* 1. '''Mild to moderate Kaposi sarcoma'''<ref>{{ cite web | title = Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents | url = https://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultOITablesOnly.pdf }}</ref> | | :* '''Mycoplasma pneumoniae''' |
| ::* Preferred regimen: initiate or optimize ART | | ::* 1. '''Pneumonia''' |
| | :::* Preferred regimen: |
| | :::* Alternative regimen: |
|
| |
|
| :* 2. '''Advanced Kaposi sarcoma (ACTG Stage T1, including disseminated cutaneous or visceral Kaposi sarcoma)'''
| |
| ::* Preferred regimen: chemotherapy (per oncology consult) {{and}} ART
| |
|
| |
|
| :* 3. '''Primary effusion lymphoma'''
| |
| ::* Preferred regimen: chemotherapy (per oncology consult) {{and}} ART
| |
| ::* Note: [[Valganciclovir]] PO or [[Ganciclovir]] IV can be used as adjunctive therapy.
| |
|
| |
| :* 4. '''Multicentric Castleman's disease'''
| |
| ::* Preferred regimen (1): [[Valganciclovir]] 900 mg PO bid for 3 weeks
| |
| ::* Preferred regimen (2): [[Ganciclovir]] 5 mg/kg IV q12h for 3 weeks
| |
| ::* Preferred regimen (3): [[Valganciclovir]] 900 mg PO BID {{and}} [[Zidovudine]] 600 mg PO q6h for 7–21 days
| |
| ::* Alternative regimen: [[Rituximab]] 375 mg/m2 given weekly for 4–8 weeks (may be an alternative to or used adjunctively with antiviral therapy)
| |
|
| |
|
|
| |
|
| ==References== | | ==References== |
| {{reflist}} | | {{reflist}} |